SlideShare a Scribd company logo
REPUBLIC OF KARELIA
Key objectives and challenges, potential and
strengths
Natalia Vezikova
REPUBLIC OF KARELIA
REPUBLIC OF KARELIA
Population of the Republic,
according to the State Statistics
Committee of Russia, is 622464
people.(2018).
Population density - 3.5 people /
km2 (2015).
Urban population — 79,59 %
(2015).
818 inhabited localities :
 13 cities,
 11 urban-type settlements,
 794 — small towns,
settlements and villagers.
Healthcare facilities in Karelia
 Central Republican Hospital
 Central Children Republican Hospital
 Cancer Hospital
 Central Infectious Disease Republican Hospital
 Emergency Care Hospital
 Prenatal Center
 Central Maternity Hospital
 Central City Children Hospital
 STI Clinic
 3 Medical facilities affiliated with various Public Agencies
 4 Outpatient clinics for adults
 4 Outpatient clinics for children
 Dental services (for children and adults)
 Republican TB Clinic
 Mental Clinic
 Drug Abuse Clinic
 Central district hospitals
 Two bacteriological laboratories
WEAKNESSES
 Non-existence of a unified central bacteriological laboratory in the
Republic of Karelia:
 Central Child Republican Hospital, Central Infectious Diseases
Republican Hospital and Center for Hygiene and Epidemiology have
own bacteriological laboratories.
 Other healthcare facilities (including Central Republican Hospital)
purchase services of bacteriological laboratories located in
St.Petersburg (‘Citylab’, ‘Invitro’, ‘Liis’, etc., under Federal Law # 44)
WEAK POINTS
Non-existence of a unified database of bacteriological culture results;
Insufficient recording of nosocomial infections;
Lack of properly trained clinical microbiologists and epidemiologists;
A number of medical facilities (located in the districts of the Republic) have
no formularies (logbooks) of antimicrobials and no protocols of perioperative
antibiotic prophylaxis;
Insufficient recording of inefficient antimicrobials use and adverse effects.
STRENGTHS
 Clinical pharmacology service has been established (there are clinical
pharmacologists available in almost all large inpatient healthcare facilities);
 Antimicrobial therapy is carried out in consistency with the results of culturing;
 Antimicrobial formularies (logbooks) generated in consistency with the results
of culturing are in use in Petrozavodsk inpatient facilities;
 In consistency with the National Vaccination Plan, Republic of Karelia has
introduced Preventive Vaccination Calendar (in addition to that preventive
vaccination with anti-pneumococcal vaccine is provided for patients with
chronic lung diseases as part of the “Prevention of Disability in the Republic of
Karelia” special programme)
Antimicrobial formulary (logbook)
 Antimicrobial formulary (logbook) does not come down to a list of
antimicrobials used by physicians in medical facilities
 The formulary (logbook) contains empirical therapy programs
 To provide more precise AB ‘stationing’ , Guidelines on Infections
Treatment recommend to mark out the 1st, 2nd and 3rd line of
therapeutic agents instead of breaking down agents into agents of
primary choice and alternative ones - the latter would have allowed
for more loose interpretation.
Draft program to combat the spread of antibiotic resistance
Improving public awareness on antibiotic resistance:
 promoting public awareness on AMA use and antimicrobial
resistance
 promotion of immunization, healthy lifestyle and personal hygiene
 Involvement of medical prevention centers and “Medical Student
Volunteers” movement
 Cooperation with Petrozavodsk State University’s medical institute
 Work with mass media and other non-commercial organizations
Draft program on containment of antibiotic resistance
Training for specialists
 Schools of efficient pharmacotherapy for primary care and
hospital specialists
 Conferences on vaccine prevention and treatment of infectious
diseases that involve medical professionals participating in the
continuous medical education program.
 Training for clinical microbiologists-bacteriologists on the
premises of the Antimicrobial Chemotherapy Scientific
Research Institute at Smolensk Medical University or at other
corresponding healthcare facilities
Draft program on containment of antibiotic resistance
Control of antimicrobial resistance and antimicrobials use:
 To establish a unified microbiological laboratory (service) in the Republic of Karelia
(on the premises of the Child Republican Hospital);
 To set up a unified database of nosocomial pathogens;
 To introduce and validate antimicrobial formularies (logbooks) for non-nosocomial
and nosocomial infections; protocols for perioperative antibiotic prophylaxis (to be
introduced in the healthcare facilities);
 To improve infection control of nosocomial infections in the healthcare facilities;
 To introduce evaluation of antibacterial agents effectiveness in real clinical practice.
Draft program on containment of antibiotic resistance
Controlling the spread of multi-drug resistant bacteria:
 Collaboration between clinical pharmacologist, clinical microbiologist
and clinical epidemiologist in the medical facility;
 Introduction of protocols for the prevention of nosocomial infections in
every medical facility;
 Introduction and validation of the disinfectants formularies (logbooks)
in the medical facilities.
Central Republican Hospital
 The hospital comprises: 16 specialized clinical units, 2 intensive care
units, 15 paraclinic units, 12 diagnostic units.
 Hospital bed capacity: 822 beds in the round-the clock inpatient
department, 18 beds in the day-patient hospital, and 25 beds in the
outpatient day-care ward.
Central Republican Hospital
Department of Clinical Pharmacology and Drug Supply
2,700 to 3,000 consultations are provided annually.
Main goals of the consultations:
 AM therapy correction;
 prescription of reserve antibiotics;
 nosocomial flora analysis (ICU, surgical units, ACE units)
Central Republican Hospital
Department of Clinical Pharmacology and Drug Supply
Starting from 2001, in order to streamline the use of antimicrobial
drugs and provide control of nosocomial infections, the following
measures have been introduced in the Hospital:
 Hospital formulary (logbook) of antimicrobials including
recommendations on diagnosis and treatment of infections,
 Chief physician order on antibiotic prophylaxis of surgical
infections,
 Protocol for sepsis diagnostics and treatment.
Central Republican Hospital
Department of Clinical Pharmacology and Drug Supply
 The formulary of antimicrobial drugs is being reputedly reviewed
in consistency with new data on local antibiotic resistance,
introduction of new antimicrobial agents, and changes in
infections treatment guidelines
RESULTS FROM 2014
 Total number of biological samples sent to
the laboratory for microbiological testing -
2561
 In 2014, according to the laboratories, 4520
various infectious pathogens were identified
as a result of culturing.
 Positive samples accounted for 70% of the
total number of clinical samples.
Microbial landscape
Microorganisms Number
of strains
Frequency of
isolation,
%
Gramm-negative
bacteria
3339 73,8
Gram-positive
bacteria
1150 25,4
Fungi (Candida spp) 31 0,8
Total 4520 100
Gramm-negative bacteria
Microorganisms Number
of strains
Frequency of
isolation, %
K.pneumoniae 839 25,1
Acinetobacter spp. 606 18,1
Escherichia coli 521 15,6
P.aeruginosa 442 13,2
Proteus spp. 332 9,9
Enterobacter spp. 212 6,3
Serratia spp. 93 2,8
S.maltophilia 79 2,4
Others 215 6,6
Total 3339 100
Gram-positive bacteria
Microorganisms Number
of strains
Frequency of
isolation, %
S. aureus 405 35,2
Enterococcus spp. 378 32,9
Coagulase negative
staphylococci
158 13,7
Others 209 18,2
Total 1150 100
Acinetobacter sensitivity
P. Aeruginosa sensitivity
Klebsiella pneumoniae sensitivity,
ESBL producents
Escherichia coli sensitivity
Tests and studies results:
 Gram-negative microflora takes the lead in the etiological
structure of infections identified in the Central Republican
Hospital(73.8%)
 K.pneumoniae (18,6%), Acinetobacter spp. (13,4%), Escherichia
coli (11,5%), P.aeruginosa (9,7%), S. aureus (8,9%), Enterococcus
spp. (8,4%) predominate among all pathogens
Спасибо за внимание!
Thank you for your attention!

More Related Content

What's hot

Pharmacovigilance program of India
Pharmacovigilance program of IndiaPharmacovigilance program of India
Pharmacovigilance program of India
Dr. Ashish singh parihar
 
Spanish National Biobank Network Strategic Plan
Spanish National Biobank Network Strategic PlanSpanish National Biobank Network Strategic Plan
Spanish National Biobank Network Strategic Plan
EuroBioForum
 
32. Development vector of regulatory procedures of biological medicines in Ru...
32. Development vector of regulatory procedures of biological medicines in Ru...32. Development vector of regulatory procedures of biological medicines in Ru...
32. Development vector of regulatory procedures of biological medicines in Ru...
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
Office of Health Economics
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
RajaniKarpur
 
25 pharmaceuticals
25 pharmaceuticals25 pharmaceuticals
25 pharmaceuticals
Andreea Foral
 
GVP module VI
GVP module VIGVP module VI
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
European Centre for Disease Prevention and Control (ECDC)
 
Clinical trial regulation 536 2014
Clinical trial regulation 536 2014Clinical trial regulation 536 2014
Clinical trial regulation 536 2014
Mauro Oruezabal
 
GOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICESGOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICES
ISF COLLEGE OF PHARMACY MOGA
 
EU control strategy for avian influenza
EU control strategy for avian influenzaEU control strategy for avian influenza
EU control strategy for avian influenza
Cornelia Adlhoch
 
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudairaVery good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
才雄 呂
 
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
 
Role of bioinformatics and pharmacogenomics in drug discovery
Role of bioinformatics and pharmacogenomics in drug discoveryRole of bioinformatics and pharmacogenomics in drug discovery
Role of bioinformatics and pharmacogenomics in drug discovery
Arindam Chakraborty
 
Pharmacovigilance Programme of India (PvPI)
Pharmacovigilance Programme of India (PvPI)Pharmacovigilance Programme of India (PvPI)
Pharmacovigilance Programme of India (PvPI)
Jamshed Ahmad
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Rafi Bhat
 
Application of "One Health" in the EU
Application of "One Health" in the EUApplication of "One Health" in the EU
Application of "One Health" in the EU
Global Risk Forum GRFDavos
 
The role of artificial intelligence in drug repurposing
The role of artificial intelligence in drug repurposingThe role of artificial intelligence in drug repurposing
The role of artificial intelligence in drug repurposing
Aboul Ella Hassanien
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
Venugopal N
 
Anvisa gudelines
Anvisa gudelinesAnvisa gudelines
Anvisa gudelines
Ankit Gotecha
 

What's hot (20)

Pharmacovigilance program of India
Pharmacovigilance program of IndiaPharmacovigilance program of India
Pharmacovigilance program of India
 
Spanish National Biobank Network Strategic Plan
Spanish National Biobank Network Strategic PlanSpanish National Biobank Network Strategic Plan
Spanish National Biobank Network Strategic Plan
 
32. Development vector of regulatory procedures of biological medicines in Ru...
32. Development vector of regulatory procedures of biological medicines in Ru...32. Development vector of regulatory procedures of biological medicines in Ru...
32. Development vector of regulatory procedures of biological medicines in Ru...
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
25 pharmaceuticals
25 pharmaceuticals25 pharmaceuticals
25 pharmaceuticals
 
GVP module VI
GVP module VIGVP module VI
GVP module VI
 
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
Changes to HAI-Net ICU protocol. Carl Suetens (ECDC)
 
Clinical trial regulation 536 2014
Clinical trial regulation 536 2014Clinical trial regulation 536 2014
Clinical trial regulation 536 2014
 
GOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICESGOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICES
 
EU control strategy for avian influenza
EU control strategy for avian influenzaEU control strategy for avian influenza
EU control strategy for avian influenza
 
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudairaVery good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
Very good pmda 介紹上市後監督(英文)-s401 03 tomoko okudaira
 
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
4. Prof. Shinar Baidullaeva - National Center for Medicines, Medical Devices ...
 
Role of bioinformatics and pharmacogenomics in drug discovery
Role of bioinformatics and pharmacogenomics in drug discoveryRole of bioinformatics and pharmacogenomics in drug discovery
Role of bioinformatics and pharmacogenomics in drug discovery
 
Pharmacovigilance Programme of India (PvPI)
Pharmacovigilance Programme of India (PvPI)Pharmacovigilance Programme of India (PvPI)
Pharmacovigilance Programme of India (PvPI)
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Application of "One Health" in the EU
Application of "One Health" in the EUApplication of "One Health" in the EU
Application of "One Health" in the EU
 
The role of artificial intelligence in drug repurposing
The role of artificial intelligence in drug repurposingThe role of artificial intelligence in drug repurposing
The role of artificial intelligence in drug repurposing
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
 
Anvisa gudelines
Anvisa gudelinesAnvisa gudelines
Anvisa gudelines
 

Similar to Presentations from NW Russian regions: Karelia (EN)

Basic laboratory procedures in clinical bacteriology
Basic laboratory procedures in clinical bacteriologyBasic laboratory procedures in clinical bacteriology
Basic laboratory procedures in clinical bacteriology
amin beni
 
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemTackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Viewics
 
Presentations from NW Russian regions: Arkhangelsk
Presentations from NW Russian regions: ArkhangelskPresentations from NW Russian regions: Arkhangelsk
Presentations from NW Russian regions: Arkhangelsk
THL
 
Anti microbial program nepal
Anti microbial program nepalAnti microbial program nepal
Anti microbial program nepal
Ruzen Bajra
 
Neumonia asociada al ventilador y nosocomial guias idsa 2016
Neumonia asociada al ventilador y nosocomial guias idsa 2016Neumonia asociada al ventilador y nosocomial guias idsa 2016
Neumonia asociada al ventilador y nosocomial guias idsa 2016
Mauricio Alejandro Usme Arango
 
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
Mauricio Alejandro Usme Arango
 
Conference Paper WHO version geneva city 2006
Conference Paper  WHO version geneva city 2006Conference Paper  WHO version geneva city 2006
Conference Paper WHO version geneva city 2006
Hans Salas Maronsky
 
Cathether Acquired Urinary Tract Infection Prevention.pdf
Cathether Acquired Urinary Tract Infection Prevention.pdfCathether Acquired Urinary Tract Infection Prevention.pdf
Cathether Acquired Urinary Tract Infection Prevention.pdf
bkbk37
 
#WHO Essential List Invitro Diagnostics 2018
#WHO  Essential List Invitro Diagnostics 2018#WHO  Essential List Invitro Diagnostics 2018
#WHO Essential List Invitro Diagnostics 2018
Value Added Corporate Services (P) Ltd
 
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
Healthcare and Medical Sciences
 
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
Madiha Mushtaque
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
semualkaira
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
komalicarol
 
Aicp 065-66-narm
Aicp 065-66-narmAicp 065-66-narm
Aicp 065-66-narm
DPNet
 
Antibiotic resistance 1
Antibiotic resistance 1Antibiotic resistance 1
Antibiotic resistance 1
Raghu Prasada
 
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
La Verità
 
chapter 1
chapter 1chapter 1
chapter 1
Belete Chane
 
Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083
Dr Muktikesh Dash, MD, PGDFM
 
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
RodolfoGamarra
 
Surveillance of healthcare associated infections
Surveillance of healthcare associated infectionsSurveillance of healthcare associated infections
Surveillance of healthcare associated infections
THL
 

Similar to Presentations from NW Russian regions: Karelia (EN) (20)

Basic laboratory procedures in clinical bacteriology
Basic laboratory procedures in clinical bacteriologyBasic laboratory procedures in clinical bacteriology
Basic laboratory procedures in clinical bacteriology
 
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemTackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
 
Presentations from NW Russian regions: Arkhangelsk
Presentations from NW Russian regions: ArkhangelskPresentations from NW Russian regions: Arkhangelsk
Presentations from NW Russian regions: Arkhangelsk
 
Anti microbial program nepal
Anti microbial program nepalAnti microbial program nepal
Anti microbial program nepal
 
Neumonia asociada al ventilador y nosocomial guias idsa 2016
Neumonia asociada al ventilador y nosocomial guias idsa 2016Neumonia asociada al ventilador y nosocomial guias idsa 2016
Neumonia asociada al ventilador y nosocomial guias idsa 2016
 
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
NEUMONIA ASOCIADA AL VENTILADOR GUIA IDSA 2016
 
Conference Paper WHO version geneva city 2006
Conference Paper  WHO version geneva city 2006Conference Paper  WHO version geneva city 2006
Conference Paper WHO version geneva city 2006
 
Cathether Acquired Urinary Tract Infection Prevention.pdf
Cathether Acquired Urinary Tract Infection Prevention.pdfCathether Acquired Urinary Tract Infection Prevention.pdf
Cathether Acquired Urinary Tract Infection Prevention.pdf
 
#WHO Essential List Invitro Diagnostics 2018
#WHO  Essential List Invitro Diagnostics 2018#WHO  Essential List Invitro Diagnostics 2018
#WHO Essential List Invitro Diagnostics 2018
 
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
Relation between Quantity of Disinfectant and Antiseptics Used and Appearance...
 
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
Hospital Antibiotic Stewardship Programs - Qualitative analysis of numerous h...
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
 
Aicp 065-66-narm
Aicp 065-66-narmAicp 065-66-narm
Aicp 065-66-narm
 
Antibiotic resistance 1
Antibiotic resistance 1Antibiotic resistance 1
Antibiotic resistance 1
 
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients wi...
 
chapter 1
chapter 1chapter 1
chapter 1
 
Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083
 
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
 
Surveillance of healthcare associated infections
Surveillance of healthcare associated infectionsSurveillance of healthcare associated infections
Surveillance of healthcare associated infections
 

More from THL

Somaattinen erikoissairaanhoito 2021
Somaattinen erikoissairaanhoito 2021Somaattinen erikoissairaanhoito 2021
Somaattinen erikoissairaanhoito 2021
THL
 
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdfNiiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
THL
 
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdfYlitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
THL
 
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdfNieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
THL
 
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdfRaitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
THL
 
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
THL
 
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdfLansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
THL
 
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdfMarkkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
THL
 
Erikoissairaanhoidon hoitoonpääsy 31.08.2022
Erikoissairaanhoidon hoitoonpääsy 31.08.2022Erikoissairaanhoidon hoitoonpääsy 31.08.2022
Erikoissairaanhoidon hoitoonpääsy 31.08.2022
THL
 
Rikos- ja riita-asioiden sovittelu 2021 -tilasto
Rikos- ja riita-asioiden sovittelu 2021 -tilastoRikos- ja riita-asioiden sovittelu 2021 -tilasto
Rikos- ja riita-asioiden sovittelu 2021 -tilasto
THL
 
Synthetic Opioid Preparedness in Europe
Synthetic Opioid Preparedness in EuropeSynthetic Opioid Preparedness in Europe
Synthetic Opioid Preparedness in Europe
THL
 
Sosiaalihuollon laitos- ja asumispalvelut 2021
Sosiaalihuollon laitos- ja asumispalvelut 2021Sosiaalihuollon laitos- ja asumispalvelut 2021
Sosiaalihuollon laitos- ja asumispalvelut 2021
THL
 
Hoitoonpääsy perusterveydenhuollossa keväällä 2022
Hoitoonpääsy perusterveydenhuollossa keväällä 2022Hoitoonpääsy perusterveydenhuollossa keväällä 2022
Hoitoonpääsy perusterveydenhuollossa keväällä 2022
THL
 
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdf
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdfAktuellt om coronavaccinationer - vaccinering under sommaren.pdf
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdf
THL
 
Kort information och aktuella frågor om vaccinationer
Kort information och aktuella frågor om vaccinationerKort information och aktuella frågor om vaccinationer
Kort information och aktuella frågor om vaccinationer
THL
 
Förvaring av vacciner
Förvaring av vaccinerFörvaring av vacciner
Förvaring av vacciner
THL
 
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
THL
 
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikatauluHanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
THL
 
Ajankohtaista koronarokotuksista 2.6.2022
Ajankohtaista koronarokotuksista 2.6.2022Ajankohtaista koronarokotuksista 2.6.2022
Ajankohtaista koronarokotuksista 2.6.2022
THL
 
Tietoisku eri rokotteista
Tietoisku eri rokotteistaTietoisku eri rokotteista
Tietoisku eri rokotteista
THL
 

More from THL (20)

Somaattinen erikoissairaanhoito 2021
Somaattinen erikoissairaanhoito 2021Somaattinen erikoissairaanhoito 2021
Somaattinen erikoissairaanhoito 2021
 
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdfNiiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
Niiranen_Jalkautuvan_nuorisotyon_vaikutusten_ennakkoarviointi_27092022.pdf
 
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdfYlitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
Ylitalo_EPT_vaikutusten_ennakkoarviointi_tulevaisuudessa_27092022.pdf
 
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdfNieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
Nieminen_Niemi_Kuntaliitto_Mita_on_paatosten_EVA_Tyokalu_tutuksi_27092022.pdf
 
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdfRaitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
Raitasalo_Nuorten_paihteidenkayton_yleiskuva_10102022.pdf
 
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
Hietanen_Peltola_Jahnukainen_Miten_opiskeluhuoltopalvelut_tukevat_hyvinvointi...
 
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdfLansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
Lansikallio_Paihdekasvatus_EPT_oppilaitoksissa_10102022.pdf
 
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdfMarkkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
Markkula_Vaikuttava ehkaiseva paihdetyo_10102022.pdf
 
Erikoissairaanhoidon hoitoonpääsy 31.08.2022
Erikoissairaanhoidon hoitoonpääsy 31.08.2022Erikoissairaanhoidon hoitoonpääsy 31.08.2022
Erikoissairaanhoidon hoitoonpääsy 31.08.2022
 
Rikos- ja riita-asioiden sovittelu 2021 -tilasto
Rikos- ja riita-asioiden sovittelu 2021 -tilastoRikos- ja riita-asioiden sovittelu 2021 -tilasto
Rikos- ja riita-asioiden sovittelu 2021 -tilasto
 
Synthetic Opioid Preparedness in Europe
Synthetic Opioid Preparedness in EuropeSynthetic Opioid Preparedness in Europe
Synthetic Opioid Preparedness in Europe
 
Sosiaalihuollon laitos- ja asumispalvelut 2021
Sosiaalihuollon laitos- ja asumispalvelut 2021Sosiaalihuollon laitos- ja asumispalvelut 2021
Sosiaalihuollon laitos- ja asumispalvelut 2021
 
Hoitoonpääsy perusterveydenhuollossa keväällä 2022
Hoitoonpääsy perusterveydenhuollossa keväällä 2022Hoitoonpääsy perusterveydenhuollossa keväällä 2022
Hoitoonpääsy perusterveydenhuollossa keväällä 2022
 
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdf
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdfAktuellt om coronavaccinationer - vaccinering under sommaren.pdf
Aktuellt om coronavaccinationer - vaccinering under sommaren.pdf
 
Kort information och aktuella frågor om vaccinationer
Kort information och aktuella frågor om vaccinationerKort information och aktuella frågor om vaccinationer
Kort information och aktuella frågor om vaccinationer
 
Förvaring av vacciner
Förvaring av vaccinerFörvaring av vacciner
Förvaring av vacciner
 
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
Johannes Kohal: Henkilöstömitoituksen seurantaan tarvittavat tiedot ja tiedon...
 
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikatauluHanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
Hanna Alastalo: Henkilöstömitoituksen seurannan kehitys ja aikataulu
 
Ajankohtaista koronarokotuksista 2.6.2022
Ajankohtaista koronarokotuksista 2.6.2022Ajankohtaista koronarokotuksista 2.6.2022
Ajankohtaista koronarokotuksista 2.6.2022
 
Tietoisku eri rokotteista
Tietoisku eri rokotteistaTietoisku eri rokotteista
Tietoisku eri rokotteista
 

Recently uploaded

Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 

Recently uploaded (20)

Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 

Presentations from NW Russian regions: Karelia (EN)

  • 1. REPUBLIC OF KARELIA Key objectives and challenges, potential and strengths Natalia Vezikova
  • 3. REPUBLIC OF KARELIA Population of the Republic, according to the State Statistics Committee of Russia, is 622464 people.(2018). Population density - 3.5 people / km2 (2015). Urban population — 79,59 % (2015). 818 inhabited localities :  13 cities,  11 urban-type settlements,  794 — small towns, settlements and villagers.
  • 4. Healthcare facilities in Karelia  Central Republican Hospital  Central Children Republican Hospital  Cancer Hospital  Central Infectious Disease Republican Hospital  Emergency Care Hospital  Prenatal Center  Central Maternity Hospital  Central City Children Hospital  STI Clinic  3 Medical facilities affiliated with various Public Agencies
  • 5.  4 Outpatient clinics for adults  4 Outpatient clinics for children  Dental services (for children and adults)  Republican TB Clinic  Mental Clinic  Drug Abuse Clinic  Central district hospitals  Two bacteriological laboratories
  • 6. WEAKNESSES  Non-existence of a unified central bacteriological laboratory in the Republic of Karelia:  Central Child Republican Hospital, Central Infectious Diseases Republican Hospital and Center for Hygiene and Epidemiology have own bacteriological laboratories.  Other healthcare facilities (including Central Republican Hospital) purchase services of bacteriological laboratories located in St.Petersburg (‘Citylab’, ‘Invitro’, ‘Liis’, etc., under Federal Law # 44)
  • 7. WEAK POINTS Non-existence of a unified database of bacteriological culture results; Insufficient recording of nosocomial infections; Lack of properly trained clinical microbiologists and epidemiologists; A number of medical facilities (located in the districts of the Republic) have no formularies (logbooks) of antimicrobials and no protocols of perioperative antibiotic prophylaxis; Insufficient recording of inefficient antimicrobials use and adverse effects.
  • 8. STRENGTHS  Clinical pharmacology service has been established (there are clinical pharmacologists available in almost all large inpatient healthcare facilities);  Antimicrobial therapy is carried out in consistency with the results of culturing;  Antimicrobial formularies (logbooks) generated in consistency with the results of culturing are in use in Petrozavodsk inpatient facilities;  In consistency with the National Vaccination Plan, Republic of Karelia has introduced Preventive Vaccination Calendar (in addition to that preventive vaccination with anti-pneumococcal vaccine is provided for patients with chronic lung diseases as part of the “Prevention of Disability in the Republic of Karelia” special programme)
  • 9. Antimicrobial formulary (logbook)  Antimicrobial formulary (logbook) does not come down to a list of antimicrobials used by physicians in medical facilities  The formulary (logbook) contains empirical therapy programs  To provide more precise AB ‘stationing’ , Guidelines on Infections Treatment recommend to mark out the 1st, 2nd and 3rd line of therapeutic agents instead of breaking down agents into agents of primary choice and alternative ones - the latter would have allowed for more loose interpretation.
  • 10.
  • 11. Draft program to combat the spread of antibiotic resistance Improving public awareness on antibiotic resistance:  promoting public awareness on AMA use and antimicrobial resistance  promotion of immunization, healthy lifestyle and personal hygiene  Involvement of medical prevention centers and “Medical Student Volunteers” movement  Cooperation with Petrozavodsk State University’s medical institute  Work with mass media and other non-commercial organizations
  • 12. Draft program on containment of antibiotic resistance Training for specialists  Schools of efficient pharmacotherapy for primary care and hospital specialists  Conferences on vaccine prevention and treatment of infectious diseases that involve medical professionals participating in the continuous medical education program.  Training for clinical microbiologists-bacteriologists on the premises of the Antimicrobial Chemotherapy Scientific Research Institute at Smolensk Medical University or at other corresponding healthcare facilities
  • 13. Draft program on containment of antibiotic resistance Control of antimicrobial resistance and antimicrobials use:  To establish a unified microbiological laboratory (service) in the Republic of Karelia (on the premises of the Child Republican Hospital);  To set up a unified database of nosocomial pathogens;  To introduce and validate antimicrobial formularies (logbooks) for non-nosocomial and nosocomial infections; protocols for perioperative antibiotic prophylaxis (to be introduced in the healthcare facilities);  To improve infection control of nosocomial infections in the healthcare facilities;  To introduce evaluation of antibacterial agents effectiveness in real clinical practice.
  • 14. Draft program on containment of antibiotic resistance Controlling the spread of multi-drug resistant bacteria:  Collaboration between clinical pharmacologist, clinical microbiologist and clinical epidemiologist in the medical facility;  Introduction of protocols for the prevention of nosocomial infections in every medical facility;  Introduction and validation of the disinfectants formularies (logbooks) in the medical facilities.
  • 15. Central Republican Hospital  The hospital comprises: 16 specialized clinical units, 2 intensive care units, 15 paraclinic units, 12 diagnostic units.  Hospital bed capacity: 822 beds in the round-the clock inpatient department, 18 beds in the day-patient hospital, and 25 beds in the outpatient day-care ward.
  • 16. Central Republican Hospital Department of Clinical Pharmacology and Drug Supply 2,700 to 3,000 consultations are provided annually. Main goals of the consultations:  AM therapy correction;  prescription of reserve antibiotics;  nosocomial flora analysis (ICU, surgical units, ACE units)
  • 17. Central Republican Hospital Department of Clinical Pharmacology and Drug Supply Starting from 2001, in order to streamline the use of antimicrobial drugs and provide control of nosocomial infections, the following measures have been introduced in the Hospital:  Hospital formulary (logbook) of antimicrobials including recommendations on diagnosis and treatment of infections,  Chief physician order on antibiotic prophylaxis of surgical infections,  Protocol for sepsis diagnostics and treatment.
  • 18. Central Republican Hospital Department of Clinical Pharmacology and Drug Supply  The formulary of antimicrobial drugs is being reputedly reviewed in consistency with new data on local antibiotic resistance, introduction of new antimicrobial agents, and changes in infections treatment guidelines
  • 19. RESULTS FROM 2014  Total number of biological samples sent to the laboratory for microbiological testing - 2561  In 2014, according to the laboratories, 4520 various infectious pathogens were identified as a result of culturing.  Positive samples accounted for 70% of the total number of clinical samples.
  • 20. Microbial landscape Microorganisms Number of strains Frequency of isolation, % Gramm-negative bacteria 3339 73,8 Gram-positive bacteria 1150 25,4 Fungi (Candida spp) 31 0,8 Total 4520 100
  • 21. Gramm-negative bacteria Microorganisms Number of strains Frequency of isolation, % K.pneumoniae 839 25,1 Acinetobacter spp. 606 18,1 Escherichia coli 521 15,6 P.aeruginosa 442 13,2 Proteus spp. 332 9,9 Enterobacter spp. 212 6,3 Serratia spp. 93 2,8 S.maltophilia 79 2,4 Others 215 6,6 Total 3339 100
  • 22. Gram-positive bacteria Microorganisms Number of strains Frequency of isolation, % S. aureus 405 35,2 Enterococcus spp. 378 32,9 Coagulase negative staphylococci 158 13,7 Others 209 18,2 Total 1150 100
  • 27. Tests and studies results:  Gram-negative microflora takes the lead in the etiological structure of infections identified in the Central Republican Hospital(73.8%)  K.pneumoniae (18,6%), Acinetobacter spp. (13,4%), Escherichia coli (11,5%), P.aeruginosa (9,7%), S. aureus (8,9%), Enterococcus spp. (8,4%) predominate among all pathogens